Alan Horwich, Ph.D on Prostate Cancer at the European Cancer Congress 2013

  • A validated prognostic model of Overall Survival (Halabi S)
  • Enzalutamide monotherapy in hormone naïve prostate cancer (Smith M)
  • Results on using circulating tumor cells to assess early response (Vogelzang NJ and Scher HI)

For more information:

Abstracts: Genitourinary Malignancies - Prostate

  • Abstract: # 2851. Author(s) and title: Halabi S, Lin CY, Kelly WK, Fizazi K, Moul JW, Kaplan E, Morris MJ, Small EJ. A validated prognostic model for predicting overall survival in patients with metastatic chemotherapy naive castrate-resistant prostate cancer. [Abstract Link]
  • Abstract: # 2852. Author and title: Smith M, Borre M, Rathenborg P, Werbrouck P, Van Poppel H, Heidenreich A, Iversen P, Baskin-Bey E, Perabo F, Phung D, Tombal B. Enzalutamide (ENZA) monotherapy in hormone naive prostate cancer (HNPC): Complete analysis of a phase 2 study. [Abstract Link]
  • Abstract: # 23 Author and title: Vogelzang NJ, Petrylak DP, Fizazi K, Sternberg CN, De Wit R, Liu K, Waldman M, Barton D, Jungnelius D, Fandi A. LATE BREAKING ABSTRACT: Analysis of circulating tumor cells (CTCs) in a phase 3 study of docetaxel and prednisone (DP) with or without lenalidomide (LEN) in patients (pts) with castrate-resistant prostate cancer (CRPC): The MAINSAIL trial [Abstract Link]

This interview is produced in collaboration with

 

Copyright © 2012 InPress Media Group/Sunvalley Communication. All rights reserved. Republication or redistribution of InPress Media Group/Sunvalley Communication content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group/Sunvalley Communication. InPress Media Group/Sunvalley Communication shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Onco'Zine and Oncozine are registered trademarks and trademarks of Sunvalley Communication around the world.

Register for free to view all the Onco'Zine - The International Oncology Network content:

ADVERTISEMENT/MEDIA PARTNER

Onco'Zine is present here

Bookmark / Share

CONNECT WITH US AND

JOIN THE CONVERSATION


© 2017   Created by Peter Hofland, PhD.   Powered by

Badges  |  Report an Issue  |  Terms of Service

Find us on Google+